ÂÜÀòÂÒÂ×

Astrid T. Bratvedt is a seasoned pharmaceutical executive with extensive experience in research and development, regulatory affairs, and leadership roles. Currently serving as Chief Scientific Officer at Navamedic ASA since January 2019, Astrid previously held the position of Vice President R&D at Novicus Pharma AS, which was acquired by Navamedic in February 2019. Prior to that, Astrid spent nearly three decades at Weifa AS, where roles included Chief Scientific Officer, Vice President of Research and Development, and Vice President of New Products. Astrid's early career included positions at Nycomed Pharma as a Scientific Officer in Biopharmacy. Educational qualifications include a Master's degree in Pharmacy from the University of Oslo, complemented by further studies at Østfold University College and BI Norwegian Business School.